Towergroup: spending on OTC derivatives technology will reach $1.3 billion in 2011

Firms are spending more on technology to meet growth in the over-the-counter derivatives market. At the same time, there is pressure on technology firms to produce trading platforms to meet the increasing needs of broker-dealers, according to research by Boston-based financial research organisation Towergroup.

Towergroup predicts that spending by institutional brokers on derivatives trading technology applications will rise by a compound annual growth rate of 9.5% within the next five years, from $915 million in 2007 to $1.3 billion in 2011.

There is currently no single system offering sufficient processing capabilities for the full range of OTC derivatives. According to Towergroup, certain vanilla OTC derivatives products can be handled effectively with existing trading platforms, but processing hybrid derivatives in a standardised manner continues to challenge broker dealers.

“Due to the fast-moving nature of the OTC derivatives environment, the industry is seeing increased spending on technology, as well as increased pressure on technology firms to keep up with derivatives innovation. The successful management of these challenges will enable broker-dealers to reap the rewards associated with this high-growth, high-margin derivatives business,” said Stephen Bruel, analyst in the securities and capital markets practice at Towergroup.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Stemming the tide of rising FX settlement risk

As the trading of emerging markets currencies gathers pace and broader uncertainty sweeps across financial markets, CLS is exploring alternative services designed to mitigate settlement risk for the FX market

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here